Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1–8 µM) dose- and time-dep...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Cycle
Hlavní autoři: Prabhu, Varun V., Talekar, Mala K., Lulla, Amriti R., Kline, C. Leah B., Zhou, Lanlan, Hall, Junior, Van den Heuvel, A. Pieter J., Dicker, David T., Babar, Jawad, Grupp, Stephan A., Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Pu, Jeffrey J., Claxton, David F., Khan, Nadia, Oster, Wolfgang, Allen, Joshua E., El-Deiry, Wafik S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927637/
https://ncbi.nlm.nih.gov/pubmed/29157092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1403689
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky